These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8181029)

  • 1. The complement system in myocardial ischaemia/reperfusion injury.
    Kilgore KS; Friedrichs GS; Homeister JW; Lucchesi BR
    Cardiovasc Res; 1994 Apr; 28(4):437-44. PubMed ID: 8181029
    [No Abstract]   [Full Text] [Related]  

  • 2. Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium.
    Väkevä A; Morgan BP; Tikkanen I; Helin K; Laurila P; Meri S
    Am J Pathol; 1994 Jun; 144(6):1357-68. PubMed ID: 7515561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activation and inhibition in myocardial ischemia and reperfusion injury.
    Homeister JW; Lucchesi BR
    Annu Rev Pharmacol Toxicol; 1994; 34():17-40. PubMed ID: 8042849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of complement inhibitors in myocardial ischaemia.
    Lucchesi BR; Tanhehco EJ
    Expert Opin Investig Drugs; 2000 May; 9(5):975-91. PubMed ID: 11060721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future use of complement inhibitors for the treatment of neurological diseases.
    McGeer EG; McGeer PL
    Drugs; 1998 Jun; 55(6):739-46. PubMed ID: 9617589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A blockade of complement activation prevents rapid intestinal ischaemia-reperfusion injury by modulating mucosal mast cell degranulation in rats.
    Kimura T; Andoh A; Fujiyama Y; Saotome T; Bamba T
    Clin Exp Immunol; 1998 Mar; 111(3):484-90. PubMed ID: 9528887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium.
    Weisman HF; Bartow T; Leppo MK; Boyle MP; Marsh HC; Carson GR; Roux KH; Weisfeldt ML; Fearon DT
    Trans Assoc Am Physicians; 1990; 103():64-72. PubMed ID: 2132543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No prominent role for terminal complement activation in the early myocardial reperfusion phase following cardiac surgery.
    Kortekaas KA; van der Pol P; Lindeman JH; Baan CC; van Kooten C; Klautz RJ
    Eur J Cardiothorac Surg; 2012 May; 41(5):e117-25. PubMed ID: 22408044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits.
    Ito W; Schäfer HJ; Bhakdi S; Klask R; Hansen S; Schaarschmidt S; Schofer J; Hugo F; Hamdoch T; Mathey D
    Cardiovasc Res; 1996 Aug; 32(2):294-305. PubMed ID: 8796116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement and its implications in cardiac ischemia/reperfusion: strategies to inhibit complement.
    Monsinjon T; Richard V; Fontaine M
    Fundam Clin Pharmacol; 2001 Oct; 15(5):293-306. PubMed ID: 11903498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complement inhibition: a new therapeutic modality?].
    Porcel JM
    Med Clin (Barc); 1995 Nov; 105(18):700-2. PubMed ID: 8538252
    [No Abstract]   [Full Text] [Related]  

  • 12. Complement activation following oxidative stress.
    Collard CD; Lekowski R; Jordan JE; Agah A; Stahl GL
    Mol Immunol; 1999; 36(13-14):941-8. PubMed ID: 10698348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for targeting complement inhibitors in ischaemia/reperfusion injury.
    Dong J; Pratt JR; Smith RA; Dodd I; Sacks SH
    Mol Immunol; 1999; 36(13-14):957-63. PubMed ID: 10698350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disodium Disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion.
    Lauver DA; Lockwood SF; Lucchesi BR
    J Pharmacol Exp Ther; 2005 Aug; 314(2):686-92. PubMed ID: 15872041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to avoid complement attack in baculovirus-mediated gene delivery.
    Kaikkonen MU; Ylä-Herttuala S; Airenne KJ
    J Invertebr Pathol; 2011 Jul; 107 Suppl():S71-9. PubMed ID: 21784233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.
    Souza DG; Esser D; Bradford R; Vieira AT; Teixeira MM
    Br J Pharmacol; 2005 Aug; 145(8):1027-34. PubMed ID: 15951831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart.
    Kilgore KS; Naylor KB; Tanhehco EJ; Park JL; Booth EA; Washington RA; Lucchesi BR
    J Pharmacol Exp Ther; 1998 Jun; 285(3):987-94. PubMed ID: 9618399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terminal complement-complex in myocardial reperfusion injury.
    Beranek JT
    Cardiovasc Res; 1997 Feb; 33(2):495-6. PubMed ID: 9074715
    [No Abstract]   [Full Text] [Related]  

  • 19. Physiology and pathophysiology of complement: progress and trends.
    Morgan BP
    Crit Rev Clin Lab Sci; 1995; 32(3):265-98. PubMed ID: 7495498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement in ischemia reperfusion injury.
    Riedemann NC; Ward PA
    Am J Pathol; 2003 Feb; 162(2):363-7. PubMed ID: 12547694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.